Anzeige
Mehr »
Montag, 13.10.2025 - Börsentäglich über 12.000 News
Der Mann, der ein Lithium-Unternehmen im Wert von 1,2 Milliarden Dollar aufgebaut hat, ist zurück...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H6LX | ISIN: FR0013286259 | Ticker-Symbol: 3VG
Frankfurt
13.10.25 | 08:21
2,480 Euro
-1,20 % -0,030
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
THERANEXUS Chart 1 Jahr
5-Tage-Chart
THERANEXUS 5-Tage-Chart
RealtimeGeldBriefZeit
2,5602,61014:30

Aktuelle News zur THERANEXUS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
THERANEXUS Aktie jetzt für 0€ handeln
01.10.XFRA CAPITAL ADJUSTMENT INFORMATION - 01.10.2025273Das Instrument RIHN CH0003671440 RIETER HLDG NA SF 5 EQUITY wird cum Kapitalmassnahme gehandelt am 01.10.2025 und ex Kapitalmassnahme am 02.10.2025 The instrument RIHN CH0003671440 RIETER HLDG NA SF...
► Artikel lesen
29.09.Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercialization of Its Medicines for Rare Diseases1.046With TX01 and Batten-1, THX Pharma is entering a new strategic phase focused on regulatory approval, early access, and international commercialization of its medicines. Lyon, France - September...
► Artikel lesen
25.09.Theranexus Announces First Half 2025 Financial Results402THERANEXUS ANNOUNCES FIRST HALF 2025 FINANCIAL RESULTS Lyon, France - 25 September 2025 - 6pm CEST - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases...
► Artikel lesen
10.07.Theranexus Publishes Its Cash Position As Of 30 June 2025537Lyon, France - 10 July 2024, 6.pm CET - Theranexus, a biopharmaceutical company developing drug candidates for rare neurological diseases, today published its cash position as of 30 June 2025. On...
► Artikel lesen
13.05.Theranexus And Beyond Batten Disease Foundation Announce Strong Positive Real-world Data Supporting Batten-1 Efficacy For The Treatment Of Batten Disease669Lyon, France - Austin, Texas, United States - Mai 13, 2025 - 6.00 pm CET - Theranexus, a biopharmaceutical company developing drug candidates for rare neurological diseases and the Beyond Batten...
► Artikel lesen
29.04.Theranexus Publishes Its 2024 Full-year Results, Presents Its Progress Report And Closes Its Equity Line1.118Lyon, France - 29 April 2025 - 7pm CET - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today publishes its results for the year ending 31 December...
► Artikel lesen
30.01.THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2024 AND PRESENTS ITS PROGRESS REPORT604Lyon, France - 30 January 2025, 6pm CET - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today announces publication of its cash position as...
► Artikel lesen
23.01.THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2025429Lyon, France - January 23, 2025, 6:00 PM CET - Theranexus, an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces its financial communication agenda...
► Artikel lesen
09.01.THERANEXUS ANNOUNCES THE PUBLICATION OF ITS LETTER TO SHAREHOLDERS432Lyon, France - January 9, 2025, 6:00 PM CET - Theranexus, an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of its letter to...
► Artikel lesen
17.12.24Theranexus and Exeltis Announce Licensing Agreement to Commercialize Theranexus Tx01 for Two Rare Neurological Disorders761Exeltis will be granted an exclusive license to market and distribute Theranexus' novel formulation TX01 for the treatment of two rare neurological diseases notably in Europe.Theranexus will be eligible...
► Artikel lesen
17.12.24Theranexus Presents an Update of its Cash Position and Financing Horizon544LYON, FRANCE / ACCESSWIRE / December 17, 2024 / Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases (the "Company"), today presents an update of its cash...
► Artikel lesen
19.11.24THERANEXUS: Update on the Theranexus' Batten-1 project in CLN3 Batten's disease602A communication by BBDF and Theranexus of the promising results of the Batten-1 Phase I/II trial at the Child Neurology Society Annual Meeting in San Diego (California) Additional expanded use...
► Artikel lesen
23.10.24THERANEXUS ANNOUNCES ITS CASH POSITION AS OF SEPTEMBER 30, 2024378Lyon, France - October 23, 2024 - 6:00 PM CEST - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today announces its cash position as of September...
► Artikel lesen
17.10.24THERANEXUS JOINS UP WITH SYNERLAB TO PREPARE THE COMMERCIALIZATION OF ITS PEDIATRIC FORMULATION IN NIEMANN-PICK TYPE C DISEASE487Theranexus has developed the first oral solution of miglustat tailored to the needs of patients with Niemann-Pick type C disease, Theranexus is preparing to register this formulation with the...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1